thrombomodulin, tumor necrosis factor-alpha, and D-dimer. Am J Hematol 2002;70:250-3.

11. Lee JW, Kim SK, Jang PS, et al. Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation: a Korean study of 295 patients. Pediatr Blood Cancer 2016;63:1966-73.

12. Badar T, Shetty A, Bueso-Ramos C, et al. Bone marrow necrosis in acute leukemia: clinical characteristic and outcome. Am J Hematol 2015;90:769-73.

13. Pui CH, Stass S, Green A. Bone marrow necrosis in children with malignant disease. Cancer 1985;56:1522-5.

14. Shah NR, Landi DB, Kreissman SG, Kulbach E, Moran C. Presentation and outcomes for children with bone marrow necrosis and acute lymphoblastic leukemia: a literature review. J Pediatr Hematol Oncol 2011;33:e316-9.

Identifying the link between multiple myeloma and neurofibromatosis type I

TO THE EDITOR: Neurofibromatosis type I was first described by Frederich von Recklinghausen in 1882. Neurofibromatosis type I is an autosomal dominant disorder characterized by brown skin macules, iris hamartomas (Lisch nodules), and skeletal deformities [1]. Neurofibromatosis type I is a relatively common inherited disorder that affects about one in 2,500 to one in 3,000 people worldwide, irrespective of sex or ethnic origin [2]. The neurofibromatosis gene, located on chromosome 17q11.2, encodes a 220 kDa cytoplasmic protein called neurofibromin. This protein functions, in part, as a negative regulator of the Ras proto-oncogene, which is a key signaling molecule in the control of cell growth. Individuals with neurofibromatosis type I are prone to developing benign and malignant tumors of the central nervous system and peripheral nervous system. Furthermore, other cancers such as glioma of the optic pathway, glioblastoma, malignant peripheral nerve sheath tumor, gastrointestinal stromal tumor, breast cancer, and acute myeloid leukemia are associated with neurofibromatosis type I [3]. The association between multiple myeloma (MM) and neurofibromatosis type I is rare.

We describe a case of IgG-k MM with neurofibromatosis type I. A comprehensive review of the literature looking for clinical-biologic correlations helping in identifying some aspect of the pathogenesis of the disease improve the manuscript.

A 69-year-old female with anemia, monoclonal component, and back pain was found to have MM. The neurofibromatosis type I had been diagnosed 40 years before. Molecular testing for neurofibromatosis gene mutations was performed and the results showed that patient one was heterozygous for the c.6855C>A (Tyr2285Ter) mutation.

The mutation was not found in MM cells. Serum immunofixation electrophoresis and Bence-Jones immunofixation on urine evidenced the presence of an IgG monoclonal component and kappa light chains, respectively. Protein electrophoresis showed a monoclonal spike with an IgG-k monoclonal component of 0.18 mg/dL. The determination of serum free light chains detected a kappa/lambda ratio of 168. The calcium and hemoglobin levels were normal. Fluorescence in situ hybridization (FISH) analysis of purified CD138+ plasma cells identified the presence of del(13q) but did not show del(17p). In addition, a bone marrow biopsy confirmed the presence of 70% plasma cell infiltration kappa restricted. A low dose computed tomography scan showed multiple collapses localized at dorsal and lumbar vertebrae. The magnetic resonance imaging revealed a collapse localized in the lumbar region based on the involvement of MM (Fig. 1).

Therefore, the patient was diagnosed with symptomatic IgG-k MM stage III according to the International Staging System (ISS) and was judged eligible for autologous stem cell transplantation. The first line of therapy consisted of six 28-day cycles of bortezomib, thalidomide, and dexamethasone (VTD regimen) [4], from June 2019 to November 2019. A stringent complete response was achieved. Subsequently,
the patient underwent mobilization by cyclophosphamide plus granulocyte colony-stimulating factor followed by collection of peripheral blood progenitor cells; the patient is currently still waiting for the transplant procedure.

As far as we know, this is the fourth case of a possible association between MM and neurofibromatosis type 1 reported in the literature [5, 6]. However, the reason for this association is unknown. In our case, we have not observed a bad prognosis in this association. In Table 1, we summarize the clinical characteristics of the four cases reported in the literature. All the patients were affected by MM and were diagnosed with neurofibromatosis type 1.

The neurofibromatosis gene produces a GTPase-activating protein, which functions as a tumor suppressor. Either a duplication of 17q, containing the neurofibromatosis type 1 locus, or a loss of 17p containing p53 may provide the evaluation of tumor. Further, a normal or mutated neurofibromatosis type 1 gene may affect the other genes at the same locus or those in nearby loci and may contribute to tumorigenesis [7]. The increased frequency of neoplasms in neurofibromatosis type 1 patients is partly explained by the genetic basis of the disorder that results from mutations of the neurofibromatosis type 1 locus at chromosome 17. The neurofibromatosis gene is a tumor suppressor gene that encodes for neurofibromin, a GTPase-activating protein, which downregulates Ras [8, 9]. The neurofibromatosis gene mutations are likely to produce a non-functional neurofibromin protein, which results in the deregulation of Ras pathways. Recent studies have demonstrated that mutations in N-and K-ras oncogenes may play a major role in the pathogenesis of MM, which are probably more significant in the disease than previously thought [10]. Both neurofibromatosis and Ras genes participate in the signal transduction through Ras proteins [8]. The product of the Ras genes is a guanosine phosphorylated binding protein (Ras-GDP) which can be converted to the active GTP-bound form, leading to the activation of various signaling pathways that may affect growth, differentiation, and apoptosis. Mutations in Ras oncogenes promote the active GTP-binding protein, thus continuously activating downstream effectors and giving a growth advantage to malignant cells [11]. Mangues et al. [12] have found a significant increase in the incidence of lymphomas in animals that was attributed to the synergistic effect of N-ras overexpression and neurofibromatosis gene inactivation. Based on the above literature, the association of neurofibromatosis type 1 with plasma cell dyscrasia could be interpreted by common pathogenetic mechanisms through Ras pathways.

In addition, the International Myeloma Working Group consensus updated the definition for high-risk MM based on cytogenetics. Several cytogenetic abnormalities such as t(4;14), del(17p13), t(14;16), t(14;20), non hyperdiploidy, and gain (1q) that confer poor prognosis were identified [13]. Currently, FISH is the standard technique for analysis of cytogenetic abnormalities. FISH is useful to detect genomic aberrations in situ and to enumerate the percentage of cells harboring such abnormalities, but it does not detect single-nucleotide variants. For example, TP53 on chromosome 17p is detected in 7% of myelomas, yet it is mutated at a much higher frequency in myelomas based on exome sequencing [14]. The neurofibromatosis gene is located in region 17q11.2, and the MM patients with this type of p53 (17p13) cytogenetic abnormality have a shorter progression free survival and overall survival [15]. Zengin et al. [5] highlighted the pathogenetic role of cytogenetic mutations in their patient, but the patient showed a complex karyotype without an overt association with a p53 mutation. The authors concluded that the patient had the same mutation located in the 17th chromosome that can cause neurofibromatosis type I and MM. On the contrary, Accardi et al. [6] reported a case of a 59-year-old MM patient for whom FISH analysis of purified CD138+ plasma cells identified the presence of del(13q) and trisomy of chromosome 9 and 15 but did not show del(17p) and chromosome 14 rearrangements. In the other case reported by Accardi et al. [6], the authors describe an association of smoldering multiple myeloma and neurofibromatosis type 1.

In conclusion, we suggest that the association between MM and neurofibromatosis type 1 may be a mere coincidence. However, during the work-up of MM in patients with neurofibromatosis, it is important to consider the possibility of del(17) that indicated a poor prognosis. Further studies are needed to deeply explore the possible link between MM and neurofibromatosis type 1.

Table 1. Summary of case reports on NF1 and MM.

| Case No. | Age/sex | Diagnosis | NF type | Interval from NF1 and MM diagnosis | Cytogenetic | Therapy | Outcome | Ref. |
|----------|---------|-----------|---------|----------------------------------|-------------|---------|---------|------|
| 1        | 59/M    | MM IgG-Kappa | 1       | ND                              | Del 13q, tris 9 and 15 | VTD + auto-sct | VGPR   | Accardi et al. [6] |
| 2        | 76/M    | SMM IgG-Kappa | 1       | ND                              | ND          | Follow-up | ND      | Accardi et al. [6] |
| 3        | 69/F    | MM IgG-Kappa | 1       | 40 yr                           | Del 13q     | VTD     | sCR     | Our case |
| 4        | 63/M    | MM light chain disease, Lambda | 1       | ND                               | (1q+, 8q+, 13q+, i(17q), i(18q), and +M. | ND | ND | Zengin et al. [5] |

Abbreviations: auto-sct, autologous stem cell transplantation; MM, multiple myeloma; ND, not detectable; Ref, references; sCR, stringent complete response; VGPR, very good partial response; VTD, bortezomib, thalidomide and dexamethasone.
Angela Rago, Attilio Tordi, Agostina Siniscalchi, Cristina Andrizzi, Selenia Campagna, Tommaso Caravita di Toritto
Haematology Unit, ASL Roma 1, Santo Spirito Hospital of Rome, Italy

Correspondence to: Angela Rago
Haematology Unit, ASL Roma 1, Santo Spirito Hospital of Rome, Lungotevere in Sassi 1, Rome 00198, Italy
E-mail: angelarago78@gmail.com

Received on May 3, 2020; Revised on Aug. 30, 2020; Accepted on Aug. 31, 2020
https://doi.org/10.5045/br.2020.2020102

Authors’ Disclosures of Potential Conflicts of Interest
No potential conflicts of interest relevant to this article were reported.

REFERENCES
1. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multi-disciplinary approach to care. Lancet Neurol 2014;13:834-43.
2. Cimino PJ, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol 2018;148:799-811.
3. Ferner RE, Gutmann DH. Neurofibromatosis type 1 (NF1): diagnosis and management. Handb Clin Neurol 2013;115:939-55.
4. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pre-transplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012;120:1589-96.
5. Zengin N, Gönül M, Gül U, et al. Multiple myeloma in a patient with neurofibromatosis. Am J Hematol 2007;82:772.
6. Accardi F, Marchica V, Mancini C, et al. Neurofibromatosis type I and multiple myeloma coexistence: a possible link? Hematol Rep 2018;10:7457.
7. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358-60.
8. Reynolds RM, Browning GG, Nawroz I, Campbell JW. Von Recklinghausen’s neurofibromatosis: neurofibromatosis type 1. Lancet 2003;361:1552-4.
9. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist 2000;5:477-85.
10. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003;4:557-64.
11. Rebollo A, Martínez-A C. Ras proteins: recent advances and new functions. Blood 1999;94:2971-80.
12. Mangues R, Corral T, Lu S, Symmans WF, Liu L, Pellicer A. NF1 inactivation cooperates with N-ras in vivo lymphogenesis activating Erk by a mechanism independent of its Ras-GTPase accelerating activity. Oncogene 1998;17:1705-16.
13. Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016;127:2955-62.
14. Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012;97:1272-7.
15. Chan NC, Chan NP. Recurrent cytogenetic abnormalities in multiple myeloma. Methods Mol Biol 2017;1541:295-302.